EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024 16:05 ET | electroCore, Inc.
Record full year 2023 net sales of $16.0 million increased 87% over $8.6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY,...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate in Upcoming Investor Conferences
March 12, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
March 05, 2024 16:05 ET | electroCore, Inc.
ROCKAWAY, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
EC-Logo-2018_TM_CMYK.jpg
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
November 15, 2023 08:15 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Third Quarter 2023 Financial Results
November 08, 2023 16:01 ET | electroCore, Inc.
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
October 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
October 09, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
EC-Logo-2018_TM_CMYK.jpg
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD)
September 27, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
September 26, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate in the LD Micro Main Event XVI Conference
September 25, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...